

Certificate of Analysis

CDK2/cyclin A, 1 mg

Cyclin-Dependent Kinase 2/cyclin A complex, Histidine-tagged



Part Number: PR4448A

Lot Number: 1088202C

Immediate Storage: -80°C

Shipping Conditions: dry ice

5791 Van Allen Way

Carlsbad, CA 92008

Phone: 760.603.7200

Fax: 760.602.6500

www.lifetechnologies.com

Description:

Recombinant Human full length CDK2/cyclin A complex, Histidine-tagged, expressed in insect cells. No special measures were taken to activate this kinase.

Specific Activity:

4,560 nmoles of phosphate transferred to Histone H1 peptide substrate (PKTPKKAKKL) per minute per mg of total protein at 30°C. Activity determined at a final protein concentration of 0.5 µg/mL.

Concentration:

0.17 mg/mL total protein as measured using the Bradford protein assay with BSA as a standard.

Calculated **1,860 nM**.

Storage and Handling:


For maximum recovery please spin prior to use. Aliquots of the 5 µg, 10 µg and 20 µg sizes of kinase are not recommended as materials can be used in original packaging until exhausted. For larger sizes, the number of freeze/thaws may be reduced by preparing aliquots, aliquots below 20 µL are not recommended. **Please never store a kinase diluted.** If properly stored at -80°C, this product is guaranteed for 6 months from date of purchase.

Storage Buffer:

20 mM Tris (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.01% Triton® X-100, 2 mM DTT, 20% Glycerol.

QUALITY ASSURANCE

CDK2/cyclin A Activity Graph



Dilution Buffer:

20 mM Tris (pH 7.5), 0.05% Triton®X-100, 10% Glycerol, 1 mM DTT, 0.1 mg/mL BSA.

Assay Conditions:

CDK2/cyclin A was pre-diluted in enzyme dilution buffer and assayed in 20 mM Tris (pH 7.5), 5 mM MgCl₂, 100 µM ATP 100 µM Histone H1 peptide substrate (PKTPKKAKKL) and trace [³²P]-γ-ATP for 10 minutes at 30°C.

Gel Information for CDK2/cyclin A

Page Description: The SDS-PAGE and/or Native PAGE were run on 4-20% Tris-Glycine Novex® gels (Catalog #: EC6025BOX).


Lane 1: Invitrogen™ BenchMark™ Protein Ladder (Catalog #: 10747-012).

Lane 2: 0.5 µg CDK2/cyclin A

Lane 3: 1 µg CDK2/cyclin A

Lane 4: 2.5 µg CDK2/cyclin A

Lane 5: 5 µg CDK2/cyclin A



Purity:

90% as determined by a Coomassie® blue stained SDS-PAGE gel and Western Blot analysis.

Molecular Weight:

38.5 / 52.8 kDa.

Mass Spectrometry:

CDK2/cyclin A was subjected to proteolytic digest followed by mass spec analysis. The resulting MS/MS data verified CDK2/cyclin A identity by comparison against the amino acid sequence(s) of the recombinant protein.

Protein sequence alignment with reference sequence(s)

GenBank Accession Number: NP_001789.2

CDK2 Alignment

```
1 MSYYHHHHH DYDIPTTENL YFQGAMLVPR GSPWDPEFME NFQKVEKIGE GTYGVVYKAR NKLTGEVVAL KKIRLDTETE GVPSTAIREI SLLKELNHPN IVGN CDK2
1 -----ME NFQKVEKIGE GTYGVVYKAR NKLTGEVVAL KKIRLDTETE GVPSTAIREI SLLKELNHPN NP_001789.2
101 IVKLLDVIHT ENKLYLVFEF LHQDLKKFMD ASALTGIPLP LIKSYLFQLL QGLAFCHSHR VLHRDLKPQN LLINTEGAIK LADFGGLARAF GVPVRTYTHE
63 IVKLLDVIHT ENKLYLVFEF LHQDLKKFMD ASALTGIPLP LIKSYLFQLL QGLAFCHSHR VLHRDLKPQN LLINTEGAIK LADFGGLARAF GVPVRTYTHE
201 VVTLWYRAPE ILLGCKYYST AVDIWSLGCI FAEMVTRRAL FPGDSEIDQL FRIFRTLGTG DEVVWPGVTS MPDYKPSFPK WARQDFSKVV PPLDEDEGRSL
163 VVTLWYRAPE ILLGCKYYST AVDIWSLGCI FAEMVTRRAL FPGDSEIDQL FRIFRTLGTG DEVVWPGVTS MPDYKPSFPK WARQDFSKVV PPLDEDEGRSL
301 LSQMLHYDPN KRISAKAALA HPFFQDVTKP VPHLRL.
263 LSQMLHYDPN KRISAKAALA HPFFQDVTKP VPHLRL
```

GenBank Accession Number: NP_001228.1

Cyclin A Alignment

```
1 MSYYHHHHH DYDIPTTENL YFQGAMLVPR GSPWGSM LGN SAPGPATREA GSALLALQQT ALQEDQENIN PEKAAPVQQP RTRAAALAVLK SGNPRGLAQQ IVGN Cyclin A
1 -----MLGN SAPGPATREA GSALLALQQT ALQEDQENIN PEKAAPVQQP RTRAAALAVLK SGNPRGLAQQ NP_001228.1
101 QRPKTRRVAP LKDLPVNDEH VTVPPWKANS KQPAFTIHVD EAEKEAQKKP AESQKIERED ALAFNSAISL PGPRKPLVPL DYPMDGSFES PHTMDMSIVL
65 QRPKTRRVAP LKDLPVNDEH VTVPPWKANS KQPAFTIHVD EAEKEAQKKP AESQKIERED ALAFNSAISL PGPRKPLVPL DYPMDGSFES PHTMDMSIVL
201 EDEKPVSVNE VPDYHEDIHT YLREMEVKCK PKVGYMKKQP DITNSMRAIL VDWLVEVGEE YKLQNETLHL AVNYIDRFLS SMSVLRGKLQ LVGTAAMLLA
165 EDEKPVSVNE VPDYHEDIHT YLREMEVKCK PKVGYMKKQP DITNSMRAIL VDWLVEVGEE YKLQNETLHL AVNYIDRFLS SMSVLRGKLQ LVGTAAMLLA
301 SKFEEIYPPE VAEFVYITDD TYTKKQVLRM EHLVLKVLTF DLAAPTQVNF LTQYFLHQQP ANCKVESLAM FLGELSLIDA DPYLKYLPSV IAGAAFHLAL
265 SKFEEIYPPE VAEFVYITDD TYTKKQVLRM EHLVLKVLTF DLAAPTQVNF LTQYFLHQQP ANCKVESLAM FLGELSLIDA DPYLKYLPSV IAGAAFHLAL
401 YTVTGQSWPE SLIRKTGYTL ESKLPCMLDL HQTYLKAPQH AQQSIREKYK NSKYHGVSLN NPPETLNL.
365 YTVTGQSWPE SLIRKTGYTL ESKLPCMLDL HQTYLKAPQH AQQSIREKYK NSKYHGVSLN NPPETLNL
```

* highlighted residues denote differences from the reference protein sequence(s).



Tony Goossens, Engineer II, QA/QC

Date: 28/Oct/2014

For research use only. Not intended for any animal or human therapeutic or diagnostic use, unless otherwise stated.
Novex® is a registered trademark of Life Technologies Corporation.
Invitrogen™ is a trademark of Life Technologies Corporation.
BenchMark™ is a trademark of Life Technologies Corporation.
Coomassie® is a registered trademark of Imperial Chemical Industries.
Triton® is a registered trademark of Union Carbide Chemicals and Plastics Co., Inc.

For Research Use Only. Not for use in diagnostic procedures.